コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 PANVAC) or PANVAC with per injection GM-CSF (granulocyte-macrophage colony-stimulating factor).
2 at activate innate immunity (eg, recombinant granulocyte-macrophage colony-stimulating factor).
3 ignificant cytokine responses (Th1, Th2, and granulocyte-macrophage colony-stimulating factor).
4 -1(-) fraction and produced IL-22, IL-8, and granulocyte macrophage colony stimulating factor.
5 ) ligand 1 and (C-C motif) ligand 2, and the granulocyte macrophage colony-stimulating factor.
6 ared with all other treatments except CTLA-4/granulocyte macrophage colony-stimulating factor.
7 ma levels of tumor necrosis factor-alpha and granulocyte macrophage colony-stimulating factor.
8 etic cytokines interleukin (IL)-6, IL-7, and granulocyte macrophage-colony-stimulating factor.
9 XCR7, CXCL1, CXCL8, CCL2, interleukin-6, and granulocyte-macrophage colony stimulating factor.
10 marked production of IFN-gamma, IL-17A, and granulocyte-macrophage colony-stimulating factor.
11 the presence of inflammatory signals such as granulocyte-macrophage colony-stimulating factor.
12 l meningitis had autoantibodies only against granulocyte-macrophage colony-stimulating factor.
13 ins it shares with binding sites of IL-3 and granulocyte-macrophage colony-stimulating factor.
14 n pattern-recognition receptors, and produce granulocyte-macrophage colony-stimulating factor.
15 ted defect in innate immune responses toward granulocyte-macrophage colony-stimulating factor.
16 oduction of IL-10 and enhanced production of granulocyte-macrophage colony-stimulating factor.
17 multiple myeloma fusions in conjunction with granulocyte-macrophage colony-stimulating factor.
18 eron gamma, tumor necrosis factor alpha, and granulocyte-macrophage colony-stimulating factor.
19 n disease pathogenesis and possibly also for granulocyte-macrophage colony-stimulating factor.
20 nditioned to an alveolar-like phenotype with granulocyte-macrophage colony-stimulating factor.
21 V group had further enhancement of IL-10 and granulocyte-macrophage colony-stimulating factor.
22 tigen-1 and acquisition of responsiveness to granulocyte-macrophage colony-stimulating factor.
23 ns, over 2 weeks) to one metastatic site and granulocyte-macrophage colony-stimulating factor (125 mu
24 day or 25 mg/m(2) per day) on days 2-5 plus granulocyte macrophage colony-stimulating factor (250 mu
25 -23.5% (95% CI -12.4, -33.2 [P = 0.004]) for granulocyte-macrophage colony-stimulating factor, -33.4%
26 were randomized to receive human recombinant granulocyte-macrophage colony stimulating factor (64 sub
27 adermal vaccinations of IMA901 (4.13 mg) and granulocyte macrophage colony-stimulating factor (75 mug
29 xin, macrophage colony-stimulating factor or granulocyte-macrophage colony-stimulating factor, all of
30 o the splenic red pulp, where they encounter granulocyte macrophage colony-stimulating factor and int
31 or iNOS mice and cultured in the presence of granulocyte-macrophage colony-stimulating factor and hep
32 dy-mediated cell enrichment, and cultured in granulocyte-macrophage colony-stimulating factor and int
33 1 and type-17 T cells secrete cytokines (eg, granulocyte-macrophage colony-stimulating factor and int
34 monocyte chemotactic protein-1, and reduced granulocyte-macrophage colony-stimulating factor and mac
35 CD cases analyzed) had reduced responses to granulocyte-macrophage colony-stimulating factor and mar
36 L2, CCL4, and CXCL10; and the growth factors granulocyte-macrophage colony-stimulating factor and pla
37 constitutively produce human interleukin-3, granulocyte-macrophage colony-stimulating factor and Ste
38 with MS, characterized by the expression of granulocyte-macrophage colony-stimulating factor and the
39 (+) DCs acquired high langerin and CD1a with granulocyte-macrophage colony-stimulating factor and tra
40 iopsies and led to a correlative decrease in granulocyte-macrophage colony-stimulating factor and whi
41 macrophage inflammatory protein (MIP)-1beta, granulocyte macrophage colony-stimulating factor) and ad
42 alpha, interleukin-1beta, interleukin-6, and granulocyte macrophage colony-stimulating factor) and hy
43 e evasion superfamily, to antagonize GM-CSF (granulocyte macrophage colony-stimulating factor) and IL
44 7, interferon-gamma, tissue necrosis factor, granulocyte-macrophage colony-stimulating factor) and cy
45 tissue, including growth-regulated oncogene, granulocyte macrophage colony-stimulating factor, and IL
46 V secretomes including interleukin-6 (IL-6), granulocyte macrophage colony-stimulating factor, and IL
47 ctor, granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor, and ma
48 -1alpha, MIP-1beta), hematopoietic IL-7, and granulocyte macrophage colony-stimulating factor, and re
49 IL-6, granulocyte-colony stimulating factor, granulocyte-macrophage colony-stimulating factor, and C-
50 a, interferon-gamma-inducible 10-kd protein, granulocyte-macrophage colony-stimulating factor, and CR
51 terferon gamma, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and gr
52 phage inflammatory protein 1alpha and 1beta, granulocyte-macrophage colony-stimulating factor, and in
53 train that expressed human stem cell factor, granulocyte-macrophage colony-stimulating factor, and in
54 rleukin-9, interleukin-15, interferon-gamma, granulocyte-macrophage colony-stimulating factor, and mo
55 L]13, CCL26, chemokine C-X-C motif ligand 5, granulocyte-macrophage colony-stimulating factor, and th
56 press more interleukin 17, interferon gamma, granulocyte-macrophage colony-stimulating factor, and tu
57 tent myeloid progenitors with a high dose of granulocyte-macrophage colony-stimulating factor; and (i
58 is factor (TNF)-alpha, interferon-gamma, and granulocyte-macrophage colony-stimulating factor] and ni
60 to PROSTVAC (Arm V; n = 432), PROSTVAC plus granulocyte-macrophage colony-stimulating factor (Arm VG
61 id-poly-L-lysine carboxymethylcellulose) and granulocyte-macrophage colony-stimulating factor as adju
62 ls displayed higher levels of immunoreactive granulocyte-macrophage colony-stimulating factor as well
63 g), immature autologous dendritic cells, and granulocyte-macrophage colony-stimulating factor at the
64 sseminated nontuberculous mycobacteria; anti-granulocyte macrophage colony-stimulating factor autoant
65 ardial AT and performed B-cell depletion and granulocyte-macrophage colony-stimulating factor blockad
66 and dendritic cells (DCs) when cultured with granulocyte macrophage-colony-stimulating factor but not
67 production of the chemokines CCL2, CCL5, and granulocyte-macrophage colony-stimulating factor by gast
68 ter U-IRI results in sustained expression of granulocyte-macrophage colony-stimulating factor by rena
69 kines (IL-2, IL-12, IL-17, gamma interferon, granulocyte-macrophage colony-stimulating factor) by CD4
70 hoic acid, peptidoglycan, dexamethasone, and granulocyte-macrophage colony stimulating factor, by dri
71 vity and expression of the interleukin 3 and granulocyte/macrophage-colony stimulating factor common
72 RB had reduced pSTAT5 after stimulation with granulocyte-macrophage colony-stimulating factor, compar
73 s (granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor), consi
74 ificantly increased the expression levels of granulocyte-macrophage colony-stimulating factor (CSF),
75 ted expression of Il17a, Csf2 (which encodes granulocyte-macrophage colony-stimulating factor), Cxcl1
76 Mixed chimeric mice lacking B cell-derived granulocyte macrophage colony-stimulating factor develop
77 ctor-differentiated macrophages more than in granulocyte-macrophage colony-stimulating factor-differe
78 ndromic sequence TGTGGCTGCCCACA in the human granulocyte macrophage colony-stimulating factor enhance
79 This study revealed increased granulocyte-macrophage colony-stimulating factor express
80 ination with GVAX vaccination (consisting of granulocyte macrophage colony-stimulating factor-express
81 ients with PAP due to autoantibodies against granulocyte-macrophage colony-stimulating factor; geneti
83 ng: tumor necrosis factor alpha (TNF-alpha), granulocyte macrophage colony stimulating factor (GM-CSF
84 cancer subjects treated with Ipilimumab and granulocyte macrophage colony stimulating factor (GM-CSF
85 anulocyte colony stimulating factor (G-CSF), granulocyte macrophage colony stimulating factor (GM-CSF
86 and clinical studies have demonstrated that granulocyte macrophage colony-stimulating factor (GM-CSF
87 In this context, interleukin 4 (IL-4) and granulocyte macrophage colony-stimulating factor (GM-CSF
88 cial effectors of the interleukin-23 (IL-23)-granulocyte macrophage colony-stimulating factor (GM-CSF
89 langerin, when cultured with soluble ligands granulocyte macrophage colony-stimulating factor (GM-CSF
90 ectively replicate within tumors and produce granulocyte macrophage colony-stimulating factor (GM-CSF
91 d PuraMatrix(TM) peptide hydrogel containing granulocyte macrophage colony-stimulating factor (GM-CSF
93 ency virus-uninfected adults, including anti-granulocyte macrophage colony-stimulating factor (GM-CSF
95 pled to keyhole limpet hemocyanin (KLH) plus granulocyte macrophage colony-stimulating factor (GM-CSF
96 nocyte-derived macrophages (MDMs), including granulocyte macrophage colony-stimulating factor (GM-CSF
97 enhances production of the potent chemokine granulocyte macrophage colony-stimulating factor (GM-CSF
98 ates and presenting distinct combinations of granulocyte macrophage colony-stimulating factor (GM-CSF
99 time and continuous action of both FLT3L and granulocyte macrophage colony-stimulating factor (GM-CSF
100 erative capacity, constitutive activation of granulocyte macrophage colony-stimulating factor (GM-CSF
101 eptor gamma-t (RORgammat), IL-17, IL-22, and granulocyte macrophage colony-stimulating factor (GM-CSF
102 n = 3 donors] with PSC supernatants or IL-6/granulocyte macrophage colony-stimulating factor (GM-CSF
104 in the dLN is due to the local production of granulocyte macrophage colony-stimulating factor (GM-CSF
105 that induce antimicrobial activity, such as granulocyte macrophage colony-stimulating factor (GM-CSF
107 tumor to peripheral compartments showed that granulocyte macrophage colony-stimulating factor (GM-CSF
108 signature genes such as RORgammat, CCR6, and granulocyte macrophage colony-stimulating factor (GM-CSF
109 genitors after coculture with breast cancer: granulocyte macrophage colony-stimulating factor (GM-CSF
110 rophage colony-stimulating factor (M-CSF) or granulocyte macrophage colony-stimulating factor (GM-CSF
112 evidence indicates that specific cytokines, granulocyte macrophage colony-stimulating factors (GM-CS
115 tivity by clonal myeloid progenitor cells to granulocyte macrophage-colony stimulating factor (GM-CSF
116 edullary hematopoiesis was also evident, and granulocyte macrophage-colony stimulating factor (GM-CSF
117 ILC-driven colitis depends on production of granulocyte macrophage-colony stimulating factor (GM-CSF
118 selective hypersensitivity of JMML cells to granulocyte macrophage-colony-stimulating factor (GM-CSF
119 the cytokines interleukin (IL)-3, IL-5, and granulocyte macrophage-colony-stimulating factor (GM-CSF
120 MML), demonstrating that mutant Shp2 induces granulocyte macrophage-colony-stimulating factor (GM-CSF
121 ne kinase-3(Flt3) ligand-induced, but not in granulocyte macrophage-colony-stimulating factor (GM-CSF
122 corrects gain-of-function (GOF) Shp2-induced granulocyte macrophage-colony-stimulating factor (GM-CSF
123 d vascular endothelial growth factor but not granulocyte macrophage-colony-stimulating factor (GM-CSF
125 E must produce the pro-inflammatory cytokine granulocyte-macrophage colony stimulating factor (GM-CSF
126 nd the release of high immunogenic levels of granulocyte-macrophage colony stimulating factor (GM-CSF
128 odeficiency virus (SIV) vaccine coexpressing granulocyte-macrophage colony stimulating factor (GM-CSF
129 CMML cells is identified to display aberrant granulocyte-macrophage colony stimulating factor (GM-CSF
130 autologous tumor cells engineered to secrete granulocyte-macrophage colony stimulating factor (GM-CSF
131 s study, we have analyzed the involvement of granulocyte-macrophage colony stimulating factor (GM-CSF
134 1 induces the alveolar epithelium to produce granulocyte-macrophage colony-stimulating factor (GM-CSF
135 production of the pro-inflammatory cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF
137 activity during SAA treatment or blockade of granulocyte-macrophage colony-stimulating factor (GM-CSF
138 omaterial vaccine that delivers the cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF
139 s study, we tested the hypotheses that human granulocyte-macrophage colony-stimulating factor (GM-CSF
140 njections of neutralizing antibodies against granulocyte-macrophage colony-stimulating factor (GM-CSF
141 al M1-like MO, we tested the pro-M1 cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF
143 f MDSCs, generated from bone marrow cells by granulocyte-macrophage colony-stimulating factor (GM-CSF
144 es in Th1 cytokines such as IL-2, IL-15, and granulocyte-macrophage colony-stimulating factor (GM-CSF
145 ulture of murine bone marrow (BM) cells with granulocyte-macrophage colony-stimulating factor (GM-CSF
146 tory cytokines IL-17A, IFN-gamma, IL-22, and granulocyte-macrophage colony-stimulating factor (GM-CSF
147 o-controlled trial to evaluate the effect of granulocyte-macrophage colony-stimulating factor (GM-CSF
151 ulating production of the chemokine CCL2 and granulocyte-macrophage colony-stimulating factor (GM-CSF
152 metry following treatment with IL-3, IL-5 or granulocyte-macrophage colony-stimulating factor (GM-CSF
153 een shown to be dependent on TH cell-derived granulocyte-macrophage colony-stimulating factor (GM-CSF
154 D, matrix metalloproteinase (MMP)-9, IL-1Ra, granulocyte-macrophage colony-stimulating factor (GM-CSF
155 an intradermal lower abdominal injection of granulocyte-macrophage colony-stimulating factor (GM-CSF
156 by incubation of human blood monocytes with granulocyte-macrophage colony-stimulating factor (GM-CSF
157 r et al find that donor T cells that secrete granulocyte-macrophage colony-stimulating factor (GM-CSF
158 tiated into iDCs by interleukin-4 (IL-4) and granulocyte-macrophage colony-stimulating factor (GM-CSF
159 ecent studies highlight surprising roles for granulocyte-macrophage colony-stimulating factor (GM-CSF
160 ion of DCs through injection of WT mice with granulocyte-macrophage colony-stimulating factor (GM-CSF
161 anulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF
163 monary alveolar proteinosis (hPAP) caused by granulocyte-macrophage colony-stimulating factor (GM-CSF
164 1alpha, MIP-1alphaP (CCL3L1), and MIP-1beta; granulocyte-macrophage colony-stimulating factor (GM-CSF
165 sed production of interleukin 12 (IL-12) and granulocyte-macrophage colony-stimulating factor (GM-CSF
166 c-MYC) and exposure to interleukin-3 (IL-3), granulocyte-macrophage colony-stimulating factor (GM-CSF
167 teinosis is caused by autoantibodies against granulocyte-macrophage colony-stimulating factor (GM-CSF
169 ected, macroporous alginate gels loaded with granulocyte-macrophage colony-stimulating factor (GM-CSF
170 17), gamma interferon (IFN-gamma), CCL4, and granulocyte-macrophage colony-stimulating factor (GM-CSF
172 MML) is characterized by hypersensitivity to granulocyte-macrophage colony-stimulating factor (GM-CSF
174 ctional DCs in the presence of the cytokines granulocyte-macrophage colony-stimulating factor (GM-CSF
175 n the inflammatory response, as decreases in granulocyte-macrophage colony-stimulating factor (GM-CSF
176 via STAT3 and Bim, and this was inhibited by granulocyte-macrophage colony-stimulating factor (GM-CSF
177 tes of rs1059513 had increased TNF-alpha and Granulocyte-macrophage colony-stimulating factor (GM-CSF
178 ate into DCs, which were more efficient than granulocyte-macrophage colony-stimulating factor (GM-CSF
179 GD2 monoclonal antibody (MoAb) combined with granulocyte-macrophage colony-stimulating factor (GM-CSF
180 use model of PDA, we show that tumor-derived granulocyte-macrophage colony-stimulating factor (GM-CSF
181 erapy using anti-GD2 monoclonal antibody and granulocyte-macrophage colony-stimulating factor (GM-CSF
182 d progenitors and, when treated ex vivo with granulocyte-macrophage colony-stimulating factor (GM-CSF
184 hat IL-23 induced production of the cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF
186 hat was superior to that of vaccination with granulocyte-macrophage colony-stimulating factor (GM-CSF
187 ved that monocytes treated with the cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF
188 rug targets, including neurotrophins and the granulocyte-macrophage colony-stimulating factor (GM-CSF
190 otherapy-induced lymphodepletion followed by granulocyte-macrophage colony-stimulating factor (GM-CSF
191 necrosis factor (TNF) induces expression of granulocyte-macrophage colony-stimulating factor (GM-CSF
192 ty is enhanced when ch14.18 is combined with granulocyte-macrophage colony-stimulating factor (GM-CSF
194 ry PAP is characterized by the disruption of granulocyte-macrophage colony-stimulating factor (GM-CSF
195 P co-administered intradermally with 200 mug granulocyte-macrophage colony-stimulating factor (GM-CSF
196 Therefore, we investigated neutralizing granulocyte-macrophage colony-stimulating factor (GM-CSF
198 he presence of FGL2 in tumor cells inhibited granulocyte-macrophage colony-stimulating factor (GM-CSF
199 ve been extensively studied, others, such as granulocyte-macrophage colony-stimulating factor (GM-CSF
200 uction of proinflammatory mediators, such as granulocyte-macrophage colony-stimulating factor (GM-CSF
201 IFN-beta, and interleukin-4 (IL-4), but not granulocyte-macrophage colony-stimulating factor (GM-CSF
202 develop into granulocytes in the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF
204 microbiota enhances respiratory defenses via granulocyte-macrophage colony-stimulating factor (GM-CSF
206 nes/cytokines such as CCL-3 (MIP-1alpha) and granulocyte-macrophage colony-stimulating factor (GM-CSF
207 tic Ad co-expressing interleukin (IL)-12 and granulocyte-macrophage colony-stimulating factor (GM-CSF
208 ia, and a characteristic hypersensitivity to granulocyte-macrophage colony-stimulating factor (GM-CSF
212 chanistic studies suggest that the increased granulocyte-macrophage colony-stimulating factor (GM-CSF
213 releasing interleukin (IL)-1beta that drives granulocyte-macrophage colony-stimulating factor (GM-CSF
214 PPAR-gamma), which is induced by exposure to granulocyte-macrophage colony-stimulating factor (GM-CSF
215 omyelitis and had reduced productions of the granulocyte-macrophage colony-stimulating factor (GM-CSF
218 n [CAWS]), we identify an essential role for granulocyte/macrophage colony-stimulating factor (GM-CSF
219 m bone marrow progenitors in the presence of granulocyte/macrophage colony-stimulating factor (GM-CSF
220 which controls IgM production via autocrine granulocyte/macrophage colony-stimulating factor (GM-CSF
221 ar proteinosis (PAP) syndrome, disruption of granulocyte/macrophage colony-stimulating factor (GM-CSF
222 human and mouse cardiac fibroblasts produce granulocyte/macrophage colony-stimulating factor (GM-CSF
224 on of host genes coding for proinflammatory (granulocyte-macrophage colony-stimulating factor [GM-CSF
225 nterleukin-2 [IL-2]) and -independent (IL-6, granulocyte-macrophage colony-stimulating factor [GM-CSF
226 on of proinflammatory (interleukin-6 [IL-6], granulocyte-macrophage colony-stimulating factor [GM-CSF
227 gamma], interleukin 10 [IL-10], IL-13, IL-6, granulocyte-macrophage colony-stimulating factor [GM-CSF
228 cell factor [SCF], Flt-3/Flk-2 ligand [FL], granulocyte/macrophage-colony stimulating factor [GM-CSF
229 nal concentrations than controls (n = 42) of granulocyte-macrophage colony-stimulating factor [(GM-CS
230 ing a cytokine-profiling assay, we show that granulocyte-macrophage colony-stimulating factor (GMCSF)
231 10, IL-12(p70), IL-13, TNF-alpha, IFN-gamma, granulocyte-macrophage colony-stimulating factor, granul
232 of irinotecan, temozolomide, dintuximab, and granulocyte-macrophage colony-stimulating factor (I/T/DI
233 okines (eg, IL-17A, IL-22, interferon-gamma, granulocyte macrophage colony-stimulating factor, IL-13)
234 sue, inflammation increased the secretion of granulocyte macrophage-colony stimulating factor, IL-12,
235 septic shock, whereas vasopressin decreased granulocyte-macrophage colony-stimulating factor in pati
236 ed in fusogenic cytokine (interleukin-4 plus granulocyte macrophage-colony stimulating factor)-induce
237 l factor induced LHPC proliferation, whereas granulocyte-macrophage-colony stimulating factor induced
238 f numerous cytokines and chemokines, such as granulocyte macrophage colony-stimulating factor, interf
239 resulting in degranulation and secretion of granulocyte-macrophage colony-stimulating factor, interf
240 High levels of serum cytokines (granulocyte macrophage colony-stimulating factor, interl
241 terleukin-6, interleukin-10, interleukin-17, granulocyte-macrophage colony-stimulating factor, interl
242 retory levels of various cytokines including granulocyte-macrophage colony-stimulating factor, interl
243 sis in the lungs, constitutive expression of granulocyte-macrophage colony-stimulating factor, interl
244 This DC subset was stimulated with granulocyte-macrophage colony-stimulating factor, interl
245 of cytokines produced by T-helper 17 cells (granulocyte-macrophage colony-stimulating factor, interl
246 activation of the common beta subunit of the granulocyte-macrophage colony-stimulating factor/interle
250 rent elevation of serum IFNgamma IL-10, GzB, granulocyte macrophage colony-stimulating factor, macrop
252 required to determine whether treatment with granulocyte-macrophage colony stimulating factor might a
253 pro-immunogenic effects of radiotherapy with granulocyte-macrophage colony-stimulating factor might r
254 the folding of a complex lasso glycoprotein, granulocyte-macrophage colony-stimulating factor, modeli
255 Interleukin-4, interleukin-8, granulocyte macrophage colony-stimulating factor, monocy
256 on gamma, tumor necrosis factor (TNF) alpha, granulocyte-macrophage colony-stimulating factor, monocy
257 ncrease in serum interleukin (IL) -2, IL-15, granulocyte-macrophage colony-stimulating factor, natura
258 B-cell depletion or granulocyte-macrophage colony-stimulating factor neutral
259 e have demonstrated that, when cultured with granulocyte macrophage-colony-stimulating factor, neutro
260 10-11 after vaccination; and peak levels of granulocyte-macrophage-colony-stimulating factor on days
261 onsisting of irradiated ID8 cells expressing granulocyte macrophage colony-stimulating factor or FLT3
263 itol 3-kinase (PI3K) effector Akt induced by granulocyte-macrophage colony-stimulating factor or inte
264 nts were allocated (2:1) to PROSTVAC-VF plus granulocyte-macrophage colony-stimulating factor or to c
265 23% in placebo vs. 17% in patients receiving granulocyte-macrophage colony stimulating factor (p = .3
266 hemokine (C-C motif) ligand 5 (P < 0.01) and granulocyte-macrophage colony-stimulating factor (P < 0.
267 +/- 11.3 days placebo vs. 15.7 +/- 11.9 days granulocyte-macrophage colony stimulating factor, p = .1
268 +/- 10.3 days placebo vs. 10.8 +/- 10.5 days granulocyte-macrophage colony stimulating factor, p = .8
269 The combination of radiotherapy with granulocyte-macrophage colony-stimulating factor produce
270 Granulocyte macrophage colony-stimulating factor-produci
271 l clusters and 3-fold upregulated numbers of granulocyte-macrophage colony-stimulating factor-produci
272 nesis of preeclampsia, markedly up-regulated granulocyte-macrophage colony-stimulating factor product
273 related markers interferon-gamma, IL-15, and granulocyte-macrophage colony-stimulating factor protect
274 rs of this mutation had reduced responses to granulocyte-macrophage colony-stimulating factor, provid
275 ifferentiation genes, such as macrophage and granulocyte macrophage colony-stimulating factor recepto
276 (interleukin-3 receptor [IL-3R], IL-5R, and granulocyte-macrophage colony stimulating factor recepto
277 ith LNK deficiency to increase interleukin 3/granulocyte-macrophage colony-stimulating factor recepto
278 agocytic function, and surface expression of granulocyte-macrophage colony-stimulating factor recepto
279 76] RFU/cell; P < 0.0001); and expression of granulocyte-macrophage colony-stimulating factor recepto
280 ession and function of circulating leukocyte granulocyte-macrophage colony-stimulating factor recepto
281 Granulocyte-macrophage colony-stimulating factor-recepto
282 Granulocyte-macrophage colony-stimulating factor-recepto
283 s were isolated and expression of CSF2RB and granulocyte-macrophage colony-stimulating factor-respons
284 of intestinal lamina propria leukocytes with granulocyte-macrophage colony-stimulating factor resulte
285 in granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor resulte
286 r PMNs exposed in vitro to recombinant human granulocyte-macrophage colony stimulating factor (rhGM-C
288 cells are a recently described population of granulocyte macrophage colony-stimulating factor-secreti
289 GVAX pancreas, granulocyte-macrophage colony-stimulating factor-secreti
290 Furthermore, bone marrow cells cultured in granulocyte macrophage colony-stimulating factor show ac
291 /6 background does not induce hyperactivated granulocyte macrophage colony-stimulating factor signali
292 ors, such as chemokine (C-C motif) ligand 9, granulocyte-macrophage colony-stimulating factor, solubl
293 E2; this apotope, in a setting that includes granulocyte macrophage colony-stimulating factor-stimula
294 sion of FATP2 in PMN-MDSCs was controlled by granulocyte-macrophage colony-stimulating factor, throug
295 that included the immunomodulatory adjuvants granulocyte-macrophage colony-stimulating factor, Toll-l
296 In a randomized phase II trial, granulocyte-macrophage colony stimulating factor treatme
297 s increased intracellular calcium levels and granulocyte macrophage-colony-stimulating factor, tumor
298 of granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor when in
299 nts with osteosarcoma who were given inhaled granulocyte-macrophage colony-stimulating factor with fi
300 ce of myeloid progenitor hypersensitivity to granulocyte-macrophage colony-stimulating factor with my